Drugs / ABT-925
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00412620 | Dec 2006 → Oct 2007 | schizophrenia | Abbott | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-925 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00412620 ↗ |
| Known as | A-437203 | ChEMBL registry synonym — accepted as the source's own label CHEMBL439338 ↗ |
| Action | Inhibit | “ABT-925 is a selective dopamine D₃ receptor antagonist” PMID 21346607 ↗ Apr 20111“Dopamine D3 receptor antagonist” CHEMBL439338 ↗ |
| Modality | Small molecule | — CHEMBL439338 ↗ |
| Target | DRD3 | “Dopamine D3 receptor antagonist” CHEMBL439338 ↗ |